Catch up on stories from the past week (and beyond) at the Slashdot story archive


Forgot your password?

Submission + - HIV Vaccine Safe Enough To Pass Phase 1 Human Trials (

An anonymous reader writes: The first human applied clinical study (SAV CT 01) using a genetically modified killed whole-virus vaccine (SAV001-H) to evaluate its safety and tolerability was initiated in March 2012. This study is a randomized, observer-blinded, placebo-controlled study of killed whole HIV-1 vaccine (SAV001-H) following intramuscular (IM) administration. Infected men and women, 18-50 years of age, have been enrolled in this study and randomized into two treatment groups to administer killed whole HIV-1 vaccine (SAV001-H) or placebo. Sumagen announced today the patient enrollment has progressed smoothly and there have been no adverse effects observed including local reactions, signs/symptoms and laboratory toxicities after SAV001-H injection in all enrolled patients to date. With these interim results, the SAV001-H has proven safety and tolerability in humans and given Sumagen confidence for the next clinical trials to prove its immunogenicity and efficacy evaluation.
This discussion was created for logged-in users only, but now has been archived. No new comments can be posted.

HIV Vaccine Safe Enough To Pass Phase 1 Human Trials

Comments Filter:

A freelance is one who gets paid by the word -- per piece or perhaps. -- Robert Benchley